Last updated: August 13, 2026
UCB won the core Neupro patent dispute against Mylan Technologies after asserting Orange Book-listed patents covering rotigotine transdermal patches. The case concerned Mylan's Abbreviated New Drug Application and Paragraph IV challenge to generic Neupro. The principal commercial barrier was U.S. Patent No. 8,232,226, which the district court upheld against Mylan's invalidity defenses and found infringed. The Federal Circuit later affirmed the result, preserving UCB's ability to block Mylan's launch until patent protection ended.[1][2]
UCB, Inc. v. Mylan Technologies, Inc. Litigation Analysis, 2:19-cv-00148
What drug and patents were at issue in UCB v. Mylan Technologies?
The case involved Neupro, UCB's transdermal rotigotine product for Parkinson's disease and moderate-to-severe restless legs syndrome. Mylan Technologies sought FDA approval to market a generic rotigotine transdermal system.
UCB asserted patents listed in the FDA's Orange Book for Neupro, including:
| Patent |
Subject matter |
Litigation role |
| U.S. Patent No. 8,232,226 |
Rotigotine-containing transdermal therapeutic systems and related product characteristics |
Principal patent litigated |
| U.S. Patent No. 8,617,595 |
Rotigotine transdermal-system technology |
Asserted in the ANDA litigation |
| Neupro listing patents |
Product and formulation protection associated with rotigotine patches |
Basis for UCB's infringement claims |
The 226 patent addressed a transdermal delivery system using rotigotine in a formulation designed to maintain the active ingredient in a stable, non-crystalline state. That technical issue was central because rotigotine can crystallize under certain formulation and storage conditions, reducing the amount available for delivery through the skin.[1]
The case was filed in the U.S. District Court for the District of Vermont under docket number 2:19-cv-00148. UCB alleged that Mylan's ANDA filing constituted an artificial act of patent infringement under the Hatch-Waxman Act.
Why did UCB sue Mylan Technologies in 2019?
UCB filed suit after receiving notice that Mylan had submitted an ANDA containing Paragraph IV certifications against UCB's listed Neupro patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.
Under 21 U.S.C. § 355(j)(5)(B)(iii), a timely patent-infringement action generally triggers a 30-month stay of FDA approval. The stay is intended to allow the district court to resolve the dispute before FDA approval of the generic, unless the court enters an earlier decision or another statutory event ends the stay.[3]
UCB's complaint sought:
- A declaration that Mylan's proposed rotigotine patch would infringe the asserted patents;
- An injunction preventing Mylan from commercializing the product before patent expiry;
- A judgment that the asserted patent claims were valid and enforceable; and
- Other relief available under the Hatch-Waxman Act.
Mylan's defenses included non-infringement and invalidity, particularly obviousness under 35 U.S.C. § 103.
What were the main technical patent issues?
Rotigotine crystallization and transdermal delivery
The dispute focused on whether UCB's claimed patch technology represented a patentable solution to rotigotine's formulation problems. A transdermal patch must maintain the drug in a form that can migrate through the skin at a controlled rate over the product's wear period.
Mylan argued that the claimed formulation and patch characteristics would have been obvious in view of prior art addressing:
- Rotigotine delivery through the skin;
- Silicone-based adhesives;
- Drug-loaded transdermal systems;
- Techniques for reducing crystallization; and
- Conventional formulation optimization.
UCB argued that the prior art did not provide a sufficient reason to combine the relevant teachings and did not reasonably predict the claimed level of rotigotine stability and delivery performance. UCB also relied on objective indicia of non-obviousness, including the commercial success of Neupro and the technical advantages of the claimed formulation.[1]
Claim construction and infringement
The district court had to determine the meaning of technical claim terms governing the composition and physical condition of the rotigotine-containing layer. The resulting construction affected whether Mylan's proposed product fell within the scope of the asserted claims.
In an ANDA case, infringement is determined by comparing the patent claims with the product described in the ANDA, not with a commercial product that may later be manufactured. The court therefore examined Mylan's proposed formulation and manufacturing specifications as submitted to FDA.
How did the district court rule?
The district court ruled in UCB's favor on the principal patent dispute. It rejected Mylan's invalidity challenge to the asserted 226 patent and determined that Mylan's proposed generic product would infringe the relevant claims.
The ruling preserved the legal effect of UCB's patent claims against Mylan's ANDA product. Mylan could not obtain approval and launch the proposed generic in a manner that violated the court's judgment and the remaining patent term.
The decision was commercially significant because the 226 patent was the principal barrier to a generic rotigotine patch from Mylan. Even if other Orange Book patents had narrower scope or different expiration dates, a valid and infringed formulation or product patent could independently delay generic entry.
What did the Federal Circuit decide?
Mylan appealed the district court's judgment. The Federal Circuit affirmed the central result, holding that Mylan had not shown the asserted claims to be invalid on obviousness grounds.[2]
The appellate analysis focused on whether a skilled artisan would have had a reason to arrive at the claimed rotigotine transdermal system with a reasonable expectation of success. The court treated the formulation's resistance to crystallization and its delivery performance as relevant to the obviousness inquiry.
The Federal Circuit did not treat the claimed invention as a routine optimization merely because the individual components of the patch were known. The relevant question was whether the prior art would have led a skilled artisan to the claimed combination with a reasonable expectation that it would work as claimed.
The appellate outcome left the district court judgment intact. Mylan therefore did not obtain a reversal that would have cleared the asserted patent barrier.
When does Neupro lose patent exclusivity?
The key patent expiration date for the dispute was in the 2026 period. Patent-specific expiration depends on the applicable patent term, any patent-term adjustment, and the Orange Book entry for the relevant product.
| Exclusivity component |
Relevance to Mylan |
| U.S. Patent No. 8,232,226 |
Principal patent barrier; expiration in the 2026 period |
| U.S. Patent No. 8,617,595 |
Additional listed patent protection; expiration must be assessed separately |
| FDA 30-month stay |
Temporary regulatory stay triggered by the Paragraph IV litigation |
| Pediatric exclusivity |
Must be checked against the Orange Book entry; not the principal issue in the reported merits decision |
| Regulatory exclusivity |
Neupro's principal protection in this case came from patents rather than biologic exclusivity |
Patent expiry did not automatically guarantee immediate generic launch. Mylan would still need FDA approval, resolution of any remaining listed patents, and compliance with any operative judgment or injunction.
What was the Orange Book status of Neupro?
Neupro was an FDA-approved prescription transdermal system containing rotigotine. UCB's listed patents provided the statutory basis for the Paragraph IV litigation.
For commercial diligence, the Orange Book should be reviewed at the product level because it identifies:
- The approved product and dosage forms;
- Listed patents;
- Patent-use codes;
- Patent expiration information; and
- Any changes to listings or exclusivity.
A listed method-of-use patent can create a separate litigation pathway from a formulation patent. In this case, the principal risk to Mylan arose from patents directed to the transdermal product and formulation rather than from a pure method-of-use dispute.
Did Mylan challenge the patents under Paragraph IV?
Yes. The lawsuit was a Hatch-Waxman Paragraph IV case. Mylan's ANDA filing and notice to UCB created the statutory basis for UCB's infringement action.
The Paragraph IV framework shifted the dispute into federal court before commercial launch. Mylan's objective was to establish that its generic rotigotine patch would not infringe or that the asserted claims were invalid. UCB's objective was to obtain a judgment blocking FDA approval or commercial launch until the asserted patents expired.
The case illustrates the commercial value of a formulation patent. A generic applicant may be able to design around one product feature while still facing a patent covering the overall drug-in-adhesive system or stability profile.
What is the litigation status of UCB v. Mylan Technologies?
The merits litigation resulted in a judgment favoring UCB, followed by appellate review that left the core result in place. The Federal Circuit's decision eliminated Mylan's principal appellate route for overturning the validity and infringement findings.[2]
There is no basis in the reported merits decisions to characterize the case as a settlement-driven launch agreement. The controlling public record is the district court judgment and Federal Circuit affirmance.
The case should be distinguished from later generic-entry events. FDA approval, a subsequent license, a consent judgment, or a separate challenge by another generic applicant could alter market timing without changing the outcome in this docket.
What generic launch risks existed for Mylan?
Mylan faced four primary launch risks:
- Validity risk. The Federal Circuit rejected Mylan's principal obviousness challenge, leaving the asserted claims enforceable.
- Infringement risk. The proposed ANDA product was found to fall within the relevant patent claims.
- Timing risk. A launch before patent expiry could expose Mylan to injunction and damages risk.
- Regulatory risk. FDA approval remained subject to the Hatch-Waxman stay and the status of each listed patent.
A "launch at risk" strategy would have exposed Mylan to potential damages and injunctive relief if UCB prevailed. The district court and appellate outcomes made that strategy materially less attractive.
How strong was UCB's Neupro patent estate?
UCB's estate was strong against the specific Mylan product because it combined:
- Orange Book listing;
- A technically focused formulation patent;
- A claim scope tied to rotigotine transdermal delivery;
- A favorable district court judgment; and
- Federal Circuit affirmance.
Its strength was narrower outside the litigated product configuration. Patent enforceability does not mean that every rotigotine patch would infringe. A competitor could pursue a different formulation, adhesive system, drug loading, manufacturing process, or delivery profile.
The estate's commercial value also declined as the 2026 expiration period approached. After expiry, the relevant question shifted from patent validity to FDA approval status, manufacturing capacity, substitution, pricing, and pharmacy adoption.
How did this case affect the competitive landscape?
The litigation delayed or complicated Mylan's entry into the U.S. rotigotine patch market. UCB retained control over the branded Neupro franchise while the patent judgment remained effective.
The competitive implications included:
- A longer period without Mylan's approved generic competition;
- Continued reliance on UCB's manufacturing and distribution network;
- Higher barriers for other ANDA applicants targeting the same formulation;
- Greater value for design-around strategies; and
- Increased importance of any later generic approval after patent expiry.
The case did not create biologic or biosimilar risk. Neupro is a small-molecule drug delivered through a transdermal system. The relevant competitive threat was generic substitution, not a biosimilar pathway under the Public Health Service Act.
What revenue exposure did UCB face?
The litigation protected revenue from Neupro's U.S. Parkinson's disease and restless legs syndrome markets. Exact revenue exposure depended on UCB's U.S. sales, the number and timing of competing ANDAs, payer substitution, and the extent of any authorized-generic or license arrangements.
The financial risk was front-loaded around patent expiry. Once a generic rotigotine patch entered, expected effects included:
- Price erosion;
- Formulary substitution;
- Reduced branded market share;
- Lower net sales per prescription; and
- Potential loss of distribution leverage.
The case protected the remaining patent term but did not extend the underlying patent expiration date.
Key Takeaways
- UCB sued Mylan Technologies over an ANDA for generic Neupro, a rotigotine transdermal patch.
- The core dispute involved U.S. Patent No. 8,232,226 and rotigotine crystallization and delivery technology.
- Mylan's principal invalidity defense was obviousness.
- The district court ruled for UCB on validity and infringement.
- The Federal Circuit affirmed the core result.
- The principal patent protection extended into the 2026 period.
- The case involved generic risk, not biosimilar risk.
- UCB's patent estate was commercially strong against Mylan's proposed product but did not eliminate design-around or post-expiry competition.
- The public merits record reflects a litigated judgment rather than a reported settlement-based launch arrangement.
FAQs
What was UCB's main patent in the Mylan Neupro case?
U.S. Patent No. 8,232,226 was the principal patent litigated. It covered aspects of rotigotine transdermal-system technology, including formulation characteristics relevant to stability and delivery.
Was Mylan allowed to launch generic rotigotine before Neupro patent expiry?
The UCB-favorable judgment and Federal Circuit affirmance prevented Mylan from using the litigated ANDA to overcome the asserted patent barrier before the applicable patent term ended.
Did the case involve a method-of-use patent?
The dispute centered primarily on product and formulation protection for a rotigotine transdermal system. Method-of-use listings can create separate Orange Book issues, but they were not the principal basis of the reported decision.
Could another generic company challenge UCB's Neupro patents?
Yes. A separate ANDA applicant could file its own Paragraph IV certification or pursue a different formulation and patent strategy. The UCB judgment against Mylan would not automatically resolve every later applicant's claims.
Does UCB v. Mylan affect rotigotine biosimilar development?
No. Rotigotine is a small-molecule active ingredient. Competition proceeds through the ANDA generic pathway, not the biosimilar pathway.
References
-
UCB, Inc. v. Mylan Technologies, Inc., No. 2:19-cv-00148, U.S. District Court for the District of Vermont (litigation docket and district court decisions).
-
UCB, Inc. v. Mylan Technologies, Inc., Federal Circuit appellate decision affirming the district court's judgment on the asserted rotigotine patent claims.
-
Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Hatch-Waxman Amendments, 21 U.S.C. § 355(j).
-
35 U.S.C. §§ 102, 103, 271(e)(2), and 281.
